INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ibotta
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ibotta To Contact Him Directly To Discuss Their Options
If you purchased or otherwise acquired stock of Ibotta (a) pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Registration Statement') issued in connection with Ibotta's April 18, 2024 initial public offering (the 'IPO'); (b) purchased or otherwise acquired Ibotta securities between April 18, 2024, and February 26, 2025, inclusive (the 'Class Period') and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, June 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose risks concerning Ibotta's contract with The Kroger Co. ('Kroger'). Kroger's contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta's contract with another large customer, there was not a single warning of the at-will nature of Kroger's contract. Rather than disclosing the very real risk of a major client walking away at any time, Ibotta provided boilerplate warnings concerning the importance of maintaining ongoing relationships with their clients. When the true details entered the market, the lawsuit claims that investors suffered damages.
On or around April 13, 2024, Ibotta conducted its initial public offering of 6.6 million shares priced at $88.00 per share.
Then, on August 13, 2024, Ibotta issued a press release reporting its financial results for the second quarter of 2024. In the results, Ibotta reported, among other items, a net loss of $34.0 million, attributable to operating expenses that more than doubled year-over-year. Ibotta also provided a third quarter revenue forecast in the range of $91 million to $96 million, below consensus estimates.
Following this news, Ibotta stock dropped $15.53 per share, or 26%, to close at $42.66 on August 14, 2024.
On February 26, 2025, after market hours, Investing.com published an article entitled 'Ibotta shares plunge 30% as Q4 earnings miss, Q1 guidance disappoints.' This article stated, in pertinent part, that Ibotta 'saw its shares tumble [. . .] after reporting fourth-quarter earnings that fell short of expectations and providing weak guidance for the first quarter of 2025.'
Following this news, Ibotta stock dropped $29.08 per share, or 46%, to close at $34.01 on February 27, 2025.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Ibotta's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Ibotta class action, go to www.faruqilaw.com/IBTA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
7 hours ago
- The Star
Setting up of MMC marks historic milestone
KOTA KINABALU: The Malaysian Media Council (MMC) marks a historic milestone, fulfilling a 50-year vision first proposed by Tun Abdul Razak Hussein, which stakeholders have hailed as a turning point for media self-regulation. Its founding board member Datuk Sardahthisa James said the establishment represented a paradigm shift in media governance, enabling industry players to set their ethical standards and best practices while fostering constructive collaboration with the government. 'It does not mean that the government is abdicating its role in regulating the media, as it will always be needed to navigate an environment that considers certain matters sensitive. 'What the MMC does is provide an opportunity for the media to be constructive and work with the government on what these good practices should constitute,' the Daily Express editor-in-chief told Bernama yesterday. The MMC Act took effect on Saturday, with Communications Minister Datuk Fahmi Fadzil announcing the council's 12-member founding board at the Hawana 2025 celebration. James noted that while the late Abdul Razak's original vision for the MMC focused on guiding media operations, he could not have anticipated the way digital media and generative AI would revolutionise information, helping people make informed decisions. 'The MMC must now develop strategies to navigate these challenges and propose solutions that serve the Malaysian media while meeting public expectations,' he said. He added that the council's immediate challenge lies in addressing the impact of emerging technologies, including digital media and generative AI, on information dissemination while developing acceptable guidelines for Malaysian media practitioners. James, who is also part of the Bernama board of governors, highlighted the council's inclusive nature, noting significant representation from Sabah and Sarawak media, particularly from Sabah, in line with the spirit of equal partnership enshrined in the Malaysia Agreement, which determines journalistic standards. Utusan Borneo Sabah editor-in-chief Datuk Lichong Angkui expressed hope that the council would not only serve as a regulatory body but, more importantly, as a strong, independent and inclusive protector in preserving the integrity and freedom of the media. Tawau Journalists and Media Practitioners Association deputy chairman Tamrin Jamil said the council's establishment is timely to safeguard the local media industry amid rapid technological advancements.
Malaysian Reserve
11 hours ago
- Malaysian Reserve
WST Deadline: WST Investors with Losses in Excess of $100K Have Opportunity to West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
NEW YORK, June 15, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline. So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the West Pharmaceutical class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the West Pharmaceutical class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
Malaysian Reserve
16 hours ago
- Malaysian Reserve
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ibotta
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ibotta To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Ibotta (a) pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Registration Statement') issued in connection with Ibotta's April 18, 2024 initial public offering (the 'IPO'); (b) purchased or otherwise acquired Ibotta securities between April 18, 2024, and February 26, 2025, inclusive (the 'Class Period') and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose risks concerning Ibotta's contract with The Kroger Co. ('Kroger'). Kroger's contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta's contract with another large customer, there was not a single warning of the at-will nature of Kroger's contract. Rather than disclosing the very real risk of a major client walking away at any time, Ibotta provided boilerplate warnings concerning the importance of maintaining ongoing relationships with their clients. When the true details entered the market, the lawsuit claims that investors suffered damages. On or around April 13, 2024, Ibotta conducted its initial public offering of 6.6 million shares priced at $88.00 per share. Then, on August 13, 2024, Ibotta issued a press release reporting its financial results for the second quarter of 2024. In the results, Ibotta reported, among other items, a net loss of $34.0 million, attributable to operating expenses that more than doubled year-over-year. Ibotta also provided a third quarter revenue forecast in the range of $91 million to $96 million, below consensus estimates. Following this news, Ibotta stock dropped $15.53 per share, or 26%, to close at $42.66 on August 14, 2024. On February 26, 2025, after market hours, published an article entitled 'Ibotta shares plunge 30% as Q4 earnings miss, Q1 guidance disappoints.' This article stated, in pertinent part, that Ibotta 'saw its shares tumble [. . .] after reporting fourth-quarter earnings that fell short of expectations and providing weak guidance for the first quarter of 2025.' Following this news, Ibotta stock dropped $29.08 per share, or 46%, to close at $34.01 on February 27, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Ibotta's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Ibotta class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
